Cipla has announced Q1 FY22 results. Income from operations has been reported at Rs 5504 crores, a growth of 27 per cent YoY. The EBITDA is at Rs 1346 crore, 28 per cent growth YoY and PAT at Rs 715 crore at 24 per cent YoY. The company reported an overall business growth of 68 per cent YoY with strong volume traction in core therapies and COVID-19 portfolio contribution.

Umang Vohra, MD and Global CEO, Cipla, said, “At Cipla, we feel proud to have contributed extensively to the fight against COVID-19 amid the second wave by ensuring continuous supply of life-saving medicines. I am pleased to see the robust demand led traction in core therapies across our branded markets and continued cost control leading to 27 per cent revenue growth and 24.5 per cent EBITDA margin for the quarter. In India, we maintained our market-beating performance as core therapies responded to demand triggers along with support from the covid portfolio during the second wave. I am delighted to witness the continued unlocking of our respiratory franchise in the US with market share expansion in Albuterol and strengthening of the portfolio with Arformoterol launch. Our South Africa private business continues to outperform the market. Our investments in creating a differentiated API portfolio have helped drive growth in the quarter."